Qureight Closes $20 Million Series B Financing

Qureight raises $20M to expand AI-powered imaging research platform

The company specializes in providing end-to-end imaging and enterprise services for clinical trials that focus on diseases of the lung and heart.

Qureight closes $20 million Series B financing

Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 million in a Series B financing, led by Molten Ventures.

Qureight raises $20m for a chest AI to speed drug trials

Most AI imaging startups build one model per disease. A Cambridge company has raised $20m to build a single model for the whole chest. Then it can spin the rest out of that. Qureight makes AI imaging tools for lung and heart clinical trials. It closed a $20m Series B led by Molten Ventures, the […] This story continues at The Next Web

How a chat in a 400-year-old pub led to a £15m raise

Cambridge MedTech Qureight has raised £15m ($20m) in a Series B funding round led by Molten Ventures. Founded in 2020, Qureight is an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials, with a focus on lung and heart disease. Its roots date back to a conversation the founders had at Cambridge’s oldest licensed pub, the historic Pickerel Inn. Existing investors Hargreave Hale AIM VCT, XTX…

Qureight closes £15m round to scale AI imaging platform

Cambridge-based health tech company Qureight has secured $20m (£15m) in Series B funding to expand its AI-powered clinical trial imaging platform. Founded by pulmonologist Dr Muhunthan Thillai and radiologist Alessandro Ruggiero, Qureight has developed a digital infrastructure and 3D deep learning platform designed to curate, analyse, and extract precision endpoints from complex lung and heart […] The post Qureight closes £15m round to scale AI …

Exclusive: Cambridge’s Qureight raises $20M to bring AI to lung and heart clinical trials

Molten Ventures led a $20 million Series B investment in Qureight, an AI imaging platform for lung and heart clinical trials. This round brings Qureight’s funding from a £1.5 million seed in 2022 up to $20 million. The new funds will support launching an AI imaging lab and expanding into asthma, pulmonary hypertension, and bronchiectasis. Co-founder and CEO Dr Muhunthan Thillai continues to work as a consultant chest physician at Royal Papworth …